Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “hold” rating reiterated by BMO Capital Markets in a research report issued on Friday. They presently have a $72.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ target price suggests a potential downside of 2.39% from the company’s previous close.

A number of other research firms also recently commented on GILD. Jefferies Group LLC reaffirmed a “hold” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 11th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird reaffirmed an “outperform” rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Thursday, July 13th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research report on Wednesday, July 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $80.09.

Shares of Gilead Sciences (NASDAQ GILD) traded up 0.46% during trading on Friday, hitting $73.76. The stock had a trading volume of 8,874,021 shares. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $88.85. The firm has a market cap of $96.38 billion, a PE ratio of 7.80 and a beta of 1.21. The stock has a 50 day moving average of $68.32 and a 200 day moving average of $68.63.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. On average, equities analysts anticipate that Gilead Sciences will post $8.41 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “BMO Capital Markets Reaffirms “Hold” Rating for Gilead Sciences, Inc. (NASDAQ:GILD)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/07/22/bmo-capital-markets-reaffirms-hold-rating-for-gilead-sciences-inc-nasdaqgild.html.

In other news, Director John Francis Cogan sold 9,943 shares of the business’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total value of $668,666.75. Following the sale, the director now directly owns 47,562 shares in the company, valued at approximately $3,198,544.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,276 shares of company stock worth $6,230,610. Insiders own 1.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of GILD. Hall Laurie J Trustee increased its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC increased its position in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. increased its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Finally, Penserra Capital Management LLC increased its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 74.03% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.